Bio-Techne Reports Third Quarter Highlights with Mixed Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Source: PRnewswire
- Revenue Performance: Bio-Techne reported net sales of $311.4 million for the third quarter, a 2% year-over-year decline, with organic revenue also down 2%, although foreign exchange fluctuations provided a 2% positive impact, demonstrating the company's resilience amid market volatility.
- Profitability Improvement: GAAP EPS reached $0.32, a 129% increase from $0.14 in the same quarter last year, while GAAP operating income surged 95% to $75.5 million, indicating a significant enhancement in the company's profitability.
- Segment Dynamics: The Protein Sciences segment generated sales of $226.2 million, down 1% year-over-year, while the Diagnostics and Spatial Biology segment reported sales of $85.6 million, a 4% decline, reflecting varying demand across different markets.
- Future Outlook: Despite healthy biotech funding, it has not yet translated into broad-based demand, but management remains optimistic about future prospects, believing that customer purchasing activities will gradually realign, supporting the company's long-term growth strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TECH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TECH
Wall Street analysts forecast TECH stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 54.000
Low
60.00
Averages
66.14
High
72.00
Current: 54.000
Low
60.00
Averages
66.14
High
72.00
About TECH
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ananym Capital Accumulates Stake in Bio-Techne, Advocates Strategic Review
- Investor Accumulation: Ananym Capital Management has accumulated a stake in Bio-Techne, urging the company to pursue a strategic review, including a potential sale, which is expected to enhance the company's market value.
- Value Destruction Warning: In a letter to Bio-Techne's board, Ananym highlighted that shareholders have suffered value losses for years, and failure to act now risks further value destruction and capital impairment, which the board must avoid.
- Market Reaction: Bio-Techne's shares rose 4% following this news, yet the stock has dropped 8.2% over the past year, indicating market concerns and uncertainty regarding the company's future outlook.
- Company Valuation: With a current market value of $8.45 billion, Bio-Techne faces pressure from investors to enhance shareholder value through a strategic review to improve its market performance.
See More
Activist Investor Urges Bio-Techne to Consider Sale
- Investor Engagement: Ananym Capital Management has taken a significant stake in Bio-Techne, urging management to explore strategic alternatives, including a potential sale, indicating strong concern over the company's future direction.
- Performance Lag: Ananym highlighted that Bio-Techne has underperformed compared to industry peers and the broader market in recent years, emphasizing that the company may not create greater value for shareholders as an independent entity.
- Investment Critique: The investor criticized Bio-Techne's investments in adjacent business areas, arguing that these have weighed on operating margins without delivering meaningful growth, reflecting inadequacies in the company's strategic approach.
- Value Risk Warning: Ananym warned that failure to act could lead to further value destruction and permanent capital impairment, stressing that the board has a duty to explore all potential paths to preserve and enhance company value.
See More
Bio-Techne and Refeyn Launch Innovative Antibody Characterization Workflow
- Innovative Workflow: Bio-Techne and Refeyn's integrated workflow combines MauriceFlex™ and TwoMP technologies, enabling researchers to correlate charge heterogeneity with molecular weight in bispecific antibodies within a streamlined four-hour process, significantly enhancing characterization efficiency and accuracy.
- Market Demand Response: As bispecific antibodies represent the fastest-growing class in biotherapeutics, their structural complexity necessitates thorough characterization; this new approach reduces sample requirements, helping clients mitigate development risks and control costs, thereby accelerating time-to-market.
- Technical Advantages: The workflow addresses the large sample requirements of traditional methods by pairing icIEF charge variant separation with mass photometry, allowing for analysis of aggregation and size at single-molecule resolution, thus improving the efficiency of the R&D process.
- Industry Impact: With over $1.2 billion in net sales in fiscal year 2025, Bio-Techne's strong market position in life sciences is reinforced by this technological innovation, which aims to meet the urgent demand for rapid development of complex biologics in the biopharmaceutical sector.
See More
Bio-Techne and Refeyn Launch Innovative Workflow for Biosimilar Characterization
- Innovative Workflow: Bio-Techne and Refeyn's newly launched integrated workflow combines icIEF fractionation with mass photometry, enabling researchers to directly characterize charge variants and aggregation of bispecific antibodies within a streamlined four-hour process, significantly accelerating biosimilar development.
- Risk Reduction: By integrating the MauriceFlex™ system with Refeyn's TwoMP platform, the workflow allows for the analysis of charge heterogeneity and molecular weight at single-molecule resolution, thereby reducing reliance on traditional methods, mitigating manufacturing risks, and enhancing efficiency.
- Reduced Sample Requirements: The new workflow requires only nanogram-level samples, addressing the large sample demands of conventional methods, which empowers researchers to conduct in-depth characterization with less material, ultimately controlling costs and expediting decision-making processes.
- Industry Impact: As bispecific antibodies represent the fastest-growing segment in biotherapeutics, this technology's introduction will enable clients to develop complex biologics more efficiently, meeting the urgent market demand for rapid development.
See More
Bio-Techne Stock Down 17.4% Year-to-Date
- Analyst Ranking Overview: The ranking of 500 components is formed by averaging analyst opinions, reflecting market sentiment towards each component, indicating a lack of confidence in Bio-Techne among investors.
- Stock Performance Review: Year-to-date, Bio-Techne's stock has declined by approximately 17.4%, a significant drop that may impact investor confidence and lead to capital outflows.
- Market Reaction Analysis: The disparity between analyst opinions and market performance could result in increased volatility for Bio-Techne in future trading, necessitating close monitoring of market dynamics by investors.
- Overall Market Trend: Bio-Techne's performance contrasts with current market trends, suggesting that measures may be needed to restore investor confidence and improve stock performance.
See More
Comparison of TECH and PNC Stock Performance
- Stock Performance Comparison: TECH is currently trading down approximately 4.6%, while PNC is down about 0.2%, indicating differing performances that may affect investor confidence and decision-making.
- Market Sentiment Analysis: The significant decline in TECH's stock may reflect market concerns regarding its future growth potential, impacting shareholder investment strategies and decisions.
- PNC Stock Stability: Although PNC's stock has also seen a slight decline, its relatively stable performance may attract investors seeking lower-risk opportunities, thereby enhancing its market appeal.
- Investor Focus Shift: As market attention on both stocks increases, investors may reassess their portfolios to navigate current market dynamics and potential risks.
See More
Ananym Capital Accumulates Stake in Bio-Techne, Advocates Strategic Review
- Investor Accumulation: Ananym Capital Management has accumulated a stake in Bio-Techne, urging the company to pursue a strategic review, including a potential sale, which is expected to enhance the company's market value.
- Value Destruction Warning: In a letter to Bio-Techne's board, Ananym highlighted that shareholders have suffered value losses for years, and failure to act now risks further value destruction and capital impairment, which the board must avoid.
- Market Reaction: Bio-Techne's shares rose 4% following this news, yet the stock has dropped 8.2% over the past year, indicating market concerns and uncertainty regarding the company's future outlook.
- Company Valuation: With a current market value of $8.45 billion, Bio-Techne faces pressure from investors to enhance shareholder value through a strategic review to improve its market performance.
See More
Activist Investor Urges Bio-Techne to Consider Sale
- Investor Engagement: Ananym Capital Management has taken a significant stake in Bio-Techne, urging management to explore strategic alternatives, including a potential sale, indicating strong concern over the company's future direction.
- Performance Lag: Ananym highlighted that Bio-Techne has underperformed compared to industry peers and the broader market in recent years, emphasizing that the company may not create greater value for shareholders as an independent entity.
- Investment Critique: The investor criticized Bio-Techne's investments in adjacent business areas, arguing that these have weighed on operating margins without delivering meaningful growth, reflecting inadequacies in the company's strategic approach.
- Value Risk Warning: Ananym warned that failure to act could lead to further value destruction and permanent capital impairment, stressing that the board has a duty to explore all potential paths to preserve and enhance company value.
See More
Bio-Techne and Refeyn Launch Innovative Antibody Characterization Workflow
- Innovative Workflow: Bio-Techne and Refeyn's integrated workflow combines MauriceFlex™ and TwoMP technologies, enabling researchers to correlate charge heterogeneity with molecular weight in bispecific antibodies within a streamlined four-hour process, significantly enhancing characterization efficiency and accuracy.
- Market Demand Response: As bispecific antibodies represent the fastest-growing class in biotherapeutics, their structural complexity necessitates thorough characterization; this new approach reduces sample requirements, helping clients mitigate development risks and control costs, thereby accelerating time-to-market.
- Technical Advantages: The workflow addresses the large sample requirements of traditional methods by pairing icIEF charge variant separation with mass photometry, allowing for analysis of aggregation and size at single-molecule resolution, thus improving the efficiency of the R&D process.
- Industry Impact: With over $1.2 billion in net sales in fiscal year 2025, Bio-Techne's strong market position in life sciences is reinforced by this technological innovation, which aims to meet the urgent demand for rapid development of complex biologics in the biopharmaceutical sector.
See More
Bio-Techne and Refeyn Launch Innovative Workflow for Biosimilar Characterization
- Innovative Workflow: Bio-Techne and Refeyn's newly launched integrated workflow combines icIEF fractionation with mass photometry, enabling researchers to directly characterize charge variants and aggregation of bispecific antibodies within a streamlined four-hour process, significantly accelerating biosimilar development.
- Risk Reduction: By integrating the MauriceFlex™ system with Refeyn's TwoMP platform, the workflow allows for the analysis of charge heterogeneity and molecular weight at single-molecule resolution, thereby reducing reliance on traditional methods, mitigating manufacturing risks, and enhancing efficiency.
- Reduced Sample Requirements: The new workflow requires only nanogram-level samples, addressing the large sample demands of conventional methods, which empowers researchers to conduct in-depth characterization with less material, ultimately controlling costs and expediting decision-making processes.
- Industry Impact: As bispecific antibodies represent the fastest-growing segment in biotherapeutics, this technology's introduction will enable clients to develop complex biologics more efficiently, meeting the urgent market demand for rapid development.
See More
Bio-Techne Stock Down 17.4% Year-to-Date
- Analyst Ranking Overview: The ranking of 500 components is formed by averaging analyst opinions, reflecting market sentiment towards each component, indicating a lack of confidence in Bio-Techne among investors.
- Stock Performance Review: Year-to-date, Bio-Techne's stock has declined by approximately 17.4%, a significant drop that may impact investor confidence and lead to capital outflows.
- Market Reaction Analysis: The disparity between analyst opinions and market performance could result in increased volatility for Bio-Techne in future trading, necessitating close monitoring of market dynamics by investors.
- Overall Market Trend: Bio-Techne's performance contrasts with current market trends, suggesting that measures may be needed to restore investor confidence and improve stock performance.
See More
Comparison of TECH and PNC Stock Performance
- Stock Performance Comparison: TECH is currently trading down approximately 4.6%, while PNC is down about 0.2%, indicating differing performances that may affect investor confidence and decision-making.
- Market Sentiment Analysis: The significant decline in TECH's stock may reflect market concerns regarding its future growth potential, impacting shareholder investment strategies and decisions.
- PNC Stock Stability: Although PNC's stock has also seen a slight decline, its relatively stable performance may attract investors seeking lower-risk opportunities, thereby enhancing its market appeal.
- Investor Focus Shift: As market attention on both stocks increases, investors may reassess their portfolios to navigate current market dynamics and potential risks.
See More
